EarningsQ2 2026 Earnings Report
DE:2B4 Q2 2026 EPS Results
Actual EPS€0.11
Consensus EPS€0.10
Beat/MissBeat by +<€0.01
One Year Ago EPS€0.07
DE:2B4 Q2 2026 Revenue Results
Actual Revenue€31.51M
Expected Revenue€32.10M
Beat/MissMissed by -€592.84K
YoY Revenue Growth+25.07%
Earnings Announcement Details
QuarterQ2 2026
Date07/16/2026
TimeBefore Open
Conference CallThursday, July 16, 2026
DE:2B4 Upcoming Earnings
BONESUPPORT HOLDING AB's next earnings date is estimated for October 22, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2B4 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong revenue growth (30% FX-adjusted), high adjusted margins (29%), solid cash generation and pronounced U.S. launch momentum for CERAMENT G. Material positives include regulatory progress, proposed CMS reimbursement improvements, and healthy EUROW performance. Headwinds include a small set of U.S. accounts temporarily restricting usage (modestly dampening growth), higher commercial and incentive costs, minor gross margin impacts from write-downs and tariffs, and uncertainty around the timing of regulatory approvals and study publications. On balance the company's growth trajectory and scalable profitability outweigh the transitory challenges discussed.Company Guidance
Strong Revenue Growth
Net sales reached SEK 356 million in Q2 2026, representing reported growth of 25% versus Q2 2025 and growth of 30% at constant exchange rates.
Robust Adjusted Profitability
Adjusted operating result (excluding incentive program effects) was SEK 104.1 million, delivering an adjusted operating margin of 29% (reported operating result SEK 90 million).
Solid Cash Generation and Liquidity
Operating cash flows were SEK 67 million for the quarter and the company ended the quarter with a cash position of SEK 434 million after executing a SEK 83 million share buyback.
Strong U.S. Traction
U.S. sales were SEK 295 million, up 31% at constant exchange rates versus Q2 2025; the U.S. contribution improved by $35.8 million versus Q2 2025 and amounted to $140.2 million in the reported USD measure referenced on the call.
Antibiotic-eluting CERAMENT Growth
Antibiotic-eluting CERAMENT grew 40% last 12 months in the quarter at constant exchange rates, with CERAMENT G exhibiting strong ongoing launch momentum in the U.S.
Regulatory and Reimbursement Progress
De Novo regulatory process for CERAMENT V progressed as planned with responses due end of August; U.S. CMS proposed improved reimbursement and more specific procedure/identification codes for CERAMENT G (proposed ruling expected to take effect Oct 1, 2026 if finalized).
Europe and Rest of World Momentum
EUROW sales were SEK 61 million, representing 26% growth at constant exchange rates with broad-based improvement across direct, hybrid and distributor markets and stabilization in Germany.
Operational Scalability and Outlook
Management highlighted scalable business model evidenced by strong margin and cash flows, and updated full-year sales growth estimate of 33%–36% at constant exchange rates based on the Q2 run rate and a healthy pipeline.
DE:2B4 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed